Human Immunodeficiency Virus Therapeutics Market Report 2026

The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from $14.9 billion in 2025 to $15.73 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to global burden of hiv infections, widespread adoption of antiretroviral therapy, government-funded hiv treatment programs, increasing availability of generic hiv drugs, improved survival rates among hiv patients.

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to rising demand for long-acting hiv therapeutics, increasing focus on personalized hiv treatment regimens, expansion of access to hiv treatment in low and middle income countries, growing investments in next-generation antiretroviral drugs, increasing emphasis on lifelong hiv disease management. Major trends in the forecast period include increasing adoption of combination antiretroviral therapies, rising shift toward long-acting injectable hiv treatments, growing focus on early and sustained viral suppression, expansion of generic antiretroviral drug availability, increasing emphasis on treatment adherence and simplified regimens.

The rising prevalence of unprotected sexual practices is expected to drive the growth of the human immunodeficiency virus (HIV) therapeutics market in the coming years. Unprotected sexual practices refer to sexual activities without barrier protection, which increase the risk of sexually transmitted infections (STIs) and unintended pregnancies. Limited access to comprehensive sex education contributes to low awareness of safe practices, leading to higher-risk behavior, particularly among youth. HIV therapeutics help reduce the risk of transmission by suppressing viral load to undetectable levels, preventing further spread of the infection. For example, in November 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in a 2023 survey of U.S. high school students, 32% had engaged in sexual intercourse at least once, and 48% of them did not use a condom during their most recent sexual encounter. Consequently, the growing prevalence of unprotected sexual practices is driving the HIV therapeutics market.

Key companies in the HIV therapeutics market are also focusing on long-acting, highly effective prevention and treatment options, expanding access through reimbursement programs, and implementing innovative clinical strategies to improve adherence and reduce new HIV infections. For instance, in June 2025, Gilead Sciences, a US-based healthcare company, received FDA approval for Yeztugo (lenacapavir), the first and only twice-yearly injectable PrEP option. Phase 3 PURPOSE 1 and PURPOSE 2 trials demonstrated exceptional efficacy, with ≥99.9% of participants remaining HIV-negative. This long-acting injection addresses barriers such as adherence challenges, stigma, and low awareness that limit current PrEP use. Gilead is supporting broad access through insurance partnerships, co-pay support for eligible patients, and free access for uninsured individuals via assistance programs.

In July 2025, Future Pak, a US-based contract development and manufacturing organization (CDMO), acquired Theratechnologies Inc. for up to $254 million. This acquisition strengthens Future Pak’s position in the HIV therapeutics market by integrating Theratechnologies’ marketed HIV drugs, including Trogarzo and Egrifta, and leveraging their commercialization expertise to drive further growth. Theratechnologies, headquartered in Canada, is a biopharmaceutical company known for its HIV-focused portfolio, including the monoclonal antibody Trogarzo (ibalizumab) and the HIV-associated lipodystrophy treatment Egrifta (tesamorelin).

Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy's Laboratories Ltd., Mylan N.V.

North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human immunodeficiency virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hiv therapeutics market by increasing the cost of imported active pharmaceutical ingredients, formulation excipients, and specialized manufacturing equipment used in antiretroviral drug production. These impacts are most evident for branded therapies and complex drug classes in regions such as North America and Europe that depend on global pharmaceutical supply chains. Higher production costs may influence drug pricing and procurement; however, tariffs are also encouraging local manufacturing of generic antiretrovirals, regional sourcing of raw materials, and strengthened domestic pharmaceutical capabilities, supporting long-term treatment accessibility.

The human immunodeficiency virus therapeutics market research report is one of a series of new reports that provides human immunodeficiency virus therapeutics market statistics, including human immunodeficiency virus therapeutics industry global market size, regional shares, competitors with a human immunodeficiency virus therapeutics market share, detailed human immunodeficiency virus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. This human immunodeficiency virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies aimed at managing and suppressing HIV infection, primarily through antiretroviral therapy (ART). These therapies help reduce viral load, prevent progression to AIDS, and improve the quality of life for people living with HIV.

The main types of HIV therapeutics include branded drugs and generic drugs. Branded drugs are patented medicines developed and marketed under a unique name, supported by extensive research and clinical trials to ensure safety and efficacy. Key drug classes include nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are primarily used by hospitals, clinics, and specialty treatment centers.

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.